Unity Biotechnology Inc Expected To Post A Loss Of $1.65 A Share: Earnings Preview

Unity Biotechnology

04/11/2022 18:13

* UNITY Biotechnology Inc  UBX.OQ   UBX.O  is expected
to show no
change in quarterly revenue when it reports  results on November
8 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for UNITY Biotechnology
Inc
is for a loss of $1.65 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for UNITY
Biotechnology Inc is $80​, above​ its last closing price
of $2.54. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -2.70       -2.80      -1.90     Beat    32.1
 Mar. 31 2022  -2.52       -2.57      -2.80     Missed  -8.8
 Dec. 31 2021  -3.06       -3.85      -1.80     Beat    53.2​
 Sep. 30 2021  -3.77       -3.71      -3.00     Beat    19.2
 ​​Jun.        -2.91       -3.07      -3.20     Missed  -4.1
 30 2021                                                
 Mar. 31 2021  -3.70       -3.79      -2.90     Beat    23.6​
 Dec. 31 2020              -4.71      -3.70     Beat    21.5
 Sep. 30 2020  -4.91       -4.91      -5.20     Missed  -5.9
 This summary was machine generated November 4 at 18:13 GMT.  All
figures in US dollars  unless otherwise stated